Community post
Avatar
Iliana • Admin
Multiple Myeloma Discussion • August 7, 2024
New Trial Now Enrolling for Relapsed Myeloma
AI-generated title
A phase III study is open comparing a new drug called mezigdomide (CC-92480), carfilzomib and dexamethasone vs. carfilzomib and dexamethasone. Mezigdomide is part of a new class of drugs called CELMoDs. Study participants who have relapsed or refractory myeloma, at least one prior line of therapy (that included either lenalidomide or 2 cycles of an anti-CD28 monoclonal antibody) are welcome to join. Learn more: https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT05552976?cid=s_2839274
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) | BMS Clinical Trials

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) | BMS Clinical Trials

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT05552976?cid=s_2839274
Avatar

No comments yet.

Related Content